Tech Company Financing Transactions
Cadenza Bio Funding Round
Cadenza Bio, based in Oklahoma City, received $2.4 million in funding from Plains Venture Partners, Boyd Street Ventures and Cortado Ventures.
Transaction Overview
Company Name
Announced On
12/14/2023
Transaction Type
Venture Equity
Amount
$2,440,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to focus on therapeutic drug development to promote remyelination in Multiple Sclerosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Oklahoma City, OK Undisclosed
USA
Oklahoma City, OK Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Cadenza Bio is a preclinical biotechnology company focused on developing a series of novel small-molecule drugs for the treatment of demyelinating and inflammatory diseases. Our goal goes beyond incremental improvements. We are dedicated to breaking the cycle of disease and, in doing so, transforming lives. We aim not only to alleviate symptoms but to halt progression, promote repair, and restore quality of life to enable total activity, empowering patients to regain control over their health.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carol Curtis
Chief Operating Officer
Elaine Hamm
Browse more venture capital transactions:
Prev: 12/14/2023: Urban Sports Club venture capital transaction
Next: 12/14/2023: CurbWaste venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs